Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesothelin chimeric antigen receptor-modified autologous T cells
- Development stage
- Unknown
- Lead developer
- People's Liberation Army 81 Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Mesothelin chimeric antigen receptor-modified autologous T cells** is an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting mesothelin (MSLN), a cell-surface glycoprotein overexpressed in various solid tumors. Developed by the Chinese People's Liberation Army Bayi Hospital, this cell therapy is designed to treat advanced solid tumors, specifically ovarian cancer. The treatment involves isolating a patient's T cells, genetically engineering them ex vivo to express a CAR specific for mesothelin, expanding the cells, and reinfusing them into the patient. Once infused, the CAR-T cells bind to mesothelin on tumor cells, triggering T-cell activation, proliferation, and targeted tumor cell destruction. It is being evaluated in a Phase I clinical trial in China for patients with advanced ovarian cancer.
- Other names
- mesothelin CAR-T cellsmesothelin-targeted autologous CAR-T cell infusionmesothelin-targeted autologous CAR-T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on mesothelin chimeric antigen receptor-modified autologous T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesothelin chimeric antigen receptor-modified autologous T cells.